Section of Medicine
As Burnet (1954) has so ably emphasized, a crucial concept is that the body is able to distinguish between "self" and "not-self" so far as potentially antigenic substances are concerned. Any substance, potentially an antigen, which is present in the circulation at an early stage of development (in the human up to a short while before birth) is thereafter accepted as being "self" and evokes no antibody response. This has been shown experimentally in animals and occurs naturally very rarely in the human, as exemplified by the remarkable case described by Dunsford (1953) of a woman of 25, the survivor of a pair of binovular twins, who had cells of groups 0 and A in approximately equal numbers in the circulation. Potentially antigenic substances which have not been present in these early stages may evoke the production of antibody and a subsequent antigen/antibody response-this being a means used by the body to rid itself of the foreign substance.
Thus one can see several possibilities wherein body structures may come to be involved in this sort of reaction:
(1) Molecules of structures, which are normally out of contact with the circulation, may be released into it because of abnormal circumstances-for example, by trauma. A good example of this is the hypersensitivity to lens substance which may develop after intracapsular removal of cataract, when lens substance is spilled into the surrounding structures. After an interval, an intense reaction may occur in the region of the lens in the other eye. Extracapsular removal of the lens which is not associated with the escape of lens substance is not followed by such a reaction in the other eye. Sympathetic ophthalmia may also belong to this type of reaction.
It is possible that some cases-of thyroid disease with associated circulating antibody to thyroglobulin may also belong to this type.
(2) A normal body constituent may be altered so that it becomes a potent antigen. This might JUNE occur either by some alteration such as denaturing (Uwazumi, 1934) or by its combination with a foreign substance which renders it antigenic (Landsteiner, 1945) . The antibodies evoked might react not only with the original antigenic complex but also with the normal body constituent, though this has never been demonstrated, and this new tissue-antibody complex might in its turn stimulate the production of further antibody (Najjar and Fisher, 1955) . In this way a chain reaction might be produced. Antibodies may be free in the circulation or they may be present only in cells and the type of reaction produced by an antigen must depend to some extent upon the sort and situation of the antibody it evokes as well as upon its own characteristics.
The detection of antibodies can be carried out in a number of ways:
(1) Biologically, by observing the reaction to an injected antigen, or by other techniques such as passive transfer or the use of the SchultzeDale preparation.
(2) By observing the precipitation which might occur when an antigen and its antibody are mixed in the right proportions. This can be studied quantitatively-a somewhat difficult technique-or qualitatively by diffusion techniques such as those developed by Ouchterlony (1949) and Oudin (1952) .
(3) By causing either an antigen or an antibody to adhere to the surface of a foreign particle (often a red blood cell). In the presence of the appropriate antibody or antigen, or sometimes with some increase in the complexity of the system, the particles will agglutinate (Boyden, 1951; Boyden and Sorkin, 1955) .
(4) By observing in various ways the reaction between the antibody and an anti-antibody (Coombs et al., 1945) .
(5) Indirectly, by mixing antigen and antibody in the presence of "complement" and then determining whether any complement has been utilized. (Marks and Coombs, 1957) .
Renal Diseases
The evidence that auto-immunity plays a part in several renal disorders is indirect, but it is nevertheless very suggestive.
Acute diffuse glomerulonephritis (Type 1, Ellis, 1942) is known to occur in epidemics as well as sporadically and tends to follow an infection with Group A streptococci of Types 4 or 12 (Siegel et al., 1955) . Usually there is an interval of several days between the infection and the abrupt onset of renal disease. Organisms are not found in the renal lesions, and Kellett with renal lesions and, indeed, as suggested by Gairdner (1948) and by Bywaters et al. (1957) and Thomsen (1939) and others have found that complement is low in, or absent from, the serum during this acute phase. These facts all suggest that some substance is released by the streptococci which is either itself antigenic or which reacts with some glomerular capillary substance causing this to be antigenic, the interval before the onset of the disease representing the time required for antibody formation. This second possibility is suggested by the work of Glynn and Holborow (1952) (Rich, 1942b (Rich, , 1945 . Sch6nlein-Henoch purpura is also associated ensues has been well publicized, but it would seem that complete regression of proteinuria represents something much more fundamental, a point which was entirely missed in a recent leading article (Lancet, 1958) . Secondly, it can be seen from Table I (Masugi, 1934) may contain a whole spectrum of lesions from those characteristic of a progressive nephritis to reversible glomerular changes associated with massive proteinuria. Electron microscopic studies of these lesions have been made by Reid (1956) (Piel et al., 1955) .
Thyroid Disease
The place of immune reactions in thyroid disease was dramatically disclosed in 1956 when
The similarity between the findings in treated cases of Hashimoto's thyroiditis and those in myxoedema, taken in conjunction with the fact that the histological appearances in Hashimoto's thyroiditis are so closely paralleled by those found and described by Bastenie (1944) during the development of "spontaneous" myxcedema, would suggest that the two conditions are closely related.
It is interesting to note that the incidence of antibodies in patients who have developed myxoedema after operation for hyperthyroidism is the same as that found in idiopathic myxcedema and much higher than the overall incidence found in hyperthyroidism. This might eventually correlate with the findings of Greene (1950) that patients with hyperthyroidism, who after operation became myxcedematous, had glands with a considerable amount of lymphatic infiltration and germinal centres-appearances which, though local, were similar to the lesions occurring in Hashimoto's thyroiditis. Rose and Witebsky (1956) , by injecting extracts of the animal's own thyroid gland, produced lesions in the thyroids of rabbits of similar appearances to those described in man by Hashimoto. They later showed that tanned red cells, on to which, mainly, thyroglobulin was adsorbed, were agglutinated by the sera of many patients with Hashimoto's disease. Owen and Smart (1958) have also used a tanned red cell technique to detect antibodies to thyroid; some of the results are summarized in Table II. Trotter et al. (1957) found that patients with Hashimoto's disease could have complementfixing antibodies to thyroid tissue and that these were probably distinct from the precipitating antibodies. This work has been greatly extended by Roitt and Doniach (1958) who confirm that the antibodies are in all probability different from those which give precipitation reactions or agglutinated tanned red-cell preparations.
They find that very few patients with Hashimoto's disease or with myxcedema are entirely negative to all forms of antibody to thyroid and that 64% of patients with thyrotoxicosis were positive to at least one form of antibody. 68 % of patients with subacute thyroiditis also had some sort of antibodies as 27 11 439 did about one-third of those with non-toxic colloid goitres and with malignant thyroids.
In the first flush of the original findings it seemed that an auto-immune process must somehow have been started which was selfperpetuating, and which gave rise to Hashimoto's disease, if it was fairly acute; a very slow smouldering process might in the end produce myxcedema. However, it now seems that the situation is a good deal more complicated. In the first place, cases have been reported in which there was an evanescent rise in antibodies after surgery or after mumps (Felix-Davies, 1958) which would suggest that the process does not automatically become self-perpetuating. Secondly, Roitt and Doniach (1958) were unsuccessful in their attempts to demonstrate the localization of labelled antibody in the glands of monkeys, nor could they alter the morphology of the thyroid by injections of positive serum from a patient with Hashimoto's thyroiditis. Moreover, such serum did not alter the appearances of human thyroid slices in vitro.
It would seem that thyroid abnormality of any sort is often associated with the production of antibodies, either to thyroglobulin or to some component associated with microsome fraction of thyroid cells. If this process is to be selfperpetuating and to lead to destruction of the thyroid, more is needed-perhaps the changes in the basement membrane of the acini described by Stuart and Allan (1958) are one such factor.
It would perhaps be fair to state that our knowledge of the relationship of auto-immunity to thyroid disease is now a good deal more precise than it is for renal disease. It nevertheless has to be demonstrated that auto-immunity is a cause of thyroid destruction and that the circulating auto-antibodies which have been found are not merely an accompaniment of the disease process.
Professor E. G. L. Bywaters (London):
Antibodies in Rheumatism In the rheumatism field, two rather antibodylike substances, the lupus erythematosus factor and the rheumatoid arthritis factor, have appeared in the last ten years, for which everyone is trying to find an antigen-two characters in search of an author. Note that I say the rheumatism field, not the collagen diseases. It is rather ironic that the antigenicity of collagen has at last been demonstrated at a time when other substances have moved to the front of the connective tissue stage (Rothbard and Watson, 1956 Hargraves et al. (1948) meets many of these requirements. It can be transmitted by intravenous injection of serum both in man and in the female guinea-pig (Castillo et al., 1952) : it moves with gamma globulin on electrophoresis (Carlson and M6llerberg, 1958) , has the same sedimentation constant of 7S and like gamma globulin passes the placental barrier (Bridge and Foley, 1954; Berlyne et al., 1957; Mijer and Olsen, 1958; Oudsten et al., 1958; Burman and Oliver, 1958) . It gives a reaction of identity with gamma globulin on an Ouchterlony plate (Deicher et al., 1959) Friou at Yale (1957; and my colleagues at Taplow (Holborow, Weir and Johnson, 1957) , have been primarily interested in nuclear fixation, and using frozen tissue slices or white cell smears, have been able to prove that L.E. sera (with or without complement inactivation) will deposit gamma globulin on exposed nuclei: this deposited gamma globulin can then be revealed by subsequent staining with fluorescent rabbit antihuman gamma globulin. Control experiments with normal sera fail to deposit gamma globulin on the nuclei and hence the slices do not stain subsequently with the fluorescent antigamma globulin. The few other diseases, particularly liver disease, depending on the methods used and the criteria adopted. In L.E., it is often associated with various other antibody-like substances directed towards body constituents. The final proof of its antibody nature-experimental induction-has been claimed by Meischer (1957) : mitochondrial fractions of human cells produced leucoagglutinins in guinea-pigs, but nucleoprotein produced antisera which reacted with human white blood cells to produce L.E. cell-like changes.
What relation then has the L.E. factor and the L.E. cell itself to the disease: is it the cause of symptoms or an epiphenomenon like the circulating antibodies formed in infectious disease? It seems probable that some at least of the specific changes are due to this "antigen/antibody" precipitate. Thus the injection of large numbers of L.E. cells has led to glomerular lesions like wire loops (German, 1958) and itis known that the wire loop material in L.E. stains with fluorescent anti-gamma globulin (Mellors et al., 1957) . However, we are still a long way from knowing the mechanism and even farther 441 f Medicine from knowing why the body starts producing this particular antinuclear factor in the first place. Now, just as the L.E. cell factor is found in R.A., so the R.A. factor is found in L.E., but it seems to be a slightly different problem. As my colleagues have pointed out (Glynn et al., 1957) , the Rose-Waaler factor (found in at least 70% of patients with R.A., and also in L.E.)
is an antibody-like substance directed against denatured or, as the Americans say, "aggregated" gamma globulin and usually demonstrated by agglutination of sensitized red cells, or other particles. The altered gamma globulin with which R.A. factor reacts may be obtained from any of a variety of species and is improved by heating or unfolding on the surface of a particle such as a red cell.
The R.A. factor is usually demonstrated by the agglutination of sheep red blood cells coated with a subagglutinating dose of rabbit antisheep red blood cell serum, but many modifications of the original method described by Rose and his colleagues (1948) (Kunkel et al., 1958) , rubella arthritis (Johnson and Hall, 1958) , syphilis (Peltier and Christian, 1959) , and the occasional case of liver disease. The differential agglutination titre becomes progressively more positive with age in rheumatoid arthritis for no known reason (Bywaters, Carter and Scott, unpublished data) . Its chief positive association is with nodule formation (Kellgren and Ball, 1959) . Finally, although my colleagues at Taplow have produced antibody in the rabbit to rabbit red cells coated with heterologous gamma globulin, which is non-species specific in that it will agglutinate human red cells coated with incomplete anti-D serum, they failed to get this reaction with rabbit reactant coated on sheep cells (unpublished data). Thus the rabbit would not produce auto-antibody and we are awaiting a more rheumatoid rabbit.
Thus the rheumatoid factor shares with the L.E. factor the property of being apparently an antibody to a universal and ancient body constituent: why these should develop we do not know, but perhaps we would do better to ask ourselves, in the light of daily trauma and infection, why not? Why do we not all develop antibodies (if that is what these two things are) to nuclei and to slightly shop-soiled gamma globulin? Is it that some people lose their selfmarker system on Burnet's theory, or that by a Medawar's mechanism, some do not acquire tolerance in foetal life, or having acquired it, lose it? Alternatively we could ask (1) whether this is the production of an abnormal antibody to a normal antigen due to change in the antibody producing cells; (2) whether what is produced is a normal antibody to an abnormal antigen or to a normal antigen which does not normally reach the antibody apparatus, or (3) whether the normal mechanism of self-recognition has broken down. We have not yet sufficient evidence to decide between these various possibilities.
Blood Diseases
It is only within comparatively recent times that auto-immunization has been invoked as the fundamental mechanism in the pathogenesis of certain blood diseases. Although the mechanism had been hinted at by French physicians in the first decade of the century, interest in the possibility was not reawakened until Dameshek and Schwartz (1938) (Coombs) test is negative, then the probability is that the patient's himolytic anmmia is not being brought about by autoantibodies, but by a different mechanism. There may be exceptions to this in rare instances, but I think it is a good working rule.
Platelets and leucocytes are much more difficult to work with than are red cells; they tend to clump together unless great care is taken in handling them and, unlike red cells in acquired hemolytic anemia, in severe thrombocytopenia and leucopenia it is most difficult to obtain sufficient platelets or leucocytes to test, and although, for instance, various types of antiglobulin tests applied to platelets have been described (Dausset, 1956) , the results of such tests are nothing like as clear-cut as with red cells. Most workers have in fact attempted to demonstrate platelet or leucocyte auto-antibodies not by making observations on the patient's platelets or leucocytes but by looking for the antibodies in the patient's plasma or serum, using normal platelets or leucocytes as test objects. By analogy with acquired hemolytic anemia one would only be likely to demonstrate free antibody in the most severely affected cases, at a time when so much antibody was being produced that not all of it was adsorbed by the patient's leucocytes or platelets or by their precursor cells in the bone-marrow. In mild cases tests for antibodies in the patient's serum would be unlikely to be positive.
There is another complication: platelet and leucocyte groups exist so that even when the patient's serum agglutinates the test cells it is not easy to be certain that one is dealing with an auto-antibody which would also agglutinate the patient's cells, if any were available for test, or with a group iso-antibody, analogous to the well-known anti-red-cell antibodies anti-A and anti-B. Particularly is this true if the patient has been transfused previously. In theory, it should be possible to carry out the tests with platelets or leucocytes of the same group as the patient. In practice, this is not yet feasible. When it comes to idiopathic thrombocytopenic purpura (I.T.P.) the position is still more obscure (Dausset, 1956 The relationship between leucocyte autoantibodies and granulocytopenia is even less clear-cut and more uncertain than with platelet antibodies. It is known that leucocyte isoantibodies exist and they are quite commonly found in the sera of patients who have had repeated transfusions and may in fact be a cause of pyrogenic transfusion reactions (Dausset, 1957) . Leucocyte agglutinins have been demonstrated in the sera of patients with idiopathic leucopenia, but almost always only in patients who have been transfused, and such antibodies, when tested, usually fail to produce convincing agglutination of the subject's own leucocytes.
I think it probable that platelet auto-antibodies do exist and that so-called "idiopathic" (Mackay et al., 1957) . It is also a possible hypothesis that a somewhat similar change might occur in antibody-forming cells and give rise to antibody formation, yet not be associated with overt malignancy.
The last hypothesis is one that I recently proposed (Dacie, 1958) . It is purely speculative but I put it forward again in an attempt to arouse interest. Eyquem (1956) I believe that none of these treatments affects in any way the ability of the patient to rid himself entirely of his disease. This must depend on the ultimate cause of the disorder, whether it is due to some transient circumstance not likely to recur or whether the stimulus leading to the antibody formation is long-continuing or even permanent. All that steroids appear to be able to do is to damp down the rate of antibody formation and perhaps to minimize the effects of the antigen/antibody reaction. They do this much more effectively in hamolytic anemia than in I.T.P., but they cannot cure either disorder, and in my opinion the doses used should be cut down to the minimum that allows, in the himolytic-anemia patient, the hemoglobin to be reasonably stable and adequate (e.g. 10 grams per 100 ml. or more). Splenectomy helps also; in acquired hkmolytic anemia it removes an important site for the destruction of autoantibody sensitized cells as well as perhaps a site of antibody formation. The former function appears to be the more important. In I.T.P. splenectomy again probably helps by removing an organ which filters off damaged platelets from the circulation. In I.T.P. if three weeks' treatment with relatively large doses of steroids (e.g. up to 300 mg. of cortisone) fails to produce decisive benefit the therapy should be gradually discontinued.
In neither disease is splenectomy curative; it may fail utterly in the worst affected patients. This is probably because a minor improvement in the survival of red cells or platelets in a patient making overwhelming amounts of antibody is of little or no clinical benefit to the patient. In the less severely affected patient with acquired hiemolytic anemia splenectomy on the other hand may help considerably, for under these circumstances the spleen is likely to be of relatively greater importance in hemolysis. Its removal may allow compensation for hemolysis continuing at a slower rate to be effective, if not clinical cure (Chertkow "and Dacie, 1956 ).
In acquired haemolytic anmmia splenectomy should certainly be considered if himolysis continues for a matter of three months or more with no signs of improvement, particularly if the patient has to receive large doses of steroids in order to be kept in equilibrium. Transfusions should be avoided if possible, for the transfused blood is usually destroyed by the same mechanism which destroys the patient's cells. If a patient receiving large doses of steroids still needs transfusion, the outlook is grave. Splenectomy will probably be felt to be unavoidable, but in my experience the chances of a good result are not high.
